Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study involving rat vibrissa follicles, U. japonica extract was found to enhance hair growth by increasing dermal papilla cell proliferation and accelerating the anagen phase but did not inhibit 5α-reductase activity, which is linked to androgenetic alopecia.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study developed a simple and cost-effective chromatographic method for simultaneously analyzing betamethasone dipropionate and calcipotriol, achieving rapid separation within 7 minutes suitable for routine applications.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This observational study reports that a TRASER device using specific wavelengths for vascular and follicular targets showed both clinical responses and histological changes, suggesting its potential as an effective vascular and hair removal tool.

In this study, dogs fed Diet B with specific levels of dietary zinc and linoleic acid showed improved skin and hair coat conditions, evidenced by increased hair follicle growth and higher skin lipid scores.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

This study evaluated a menthol-based microemulsion for transdermal delivery of finasteride and silodosin, finding that it enhanced skin permeation and flux compared to aqueous solutions, suggesting a promising method for managing benign prostatic hyperplasia.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

This study identified new oxidative derivatives of finasteride, including a newly discovered metabolite, by using the fungus Macrophomina phaseolina.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study found that the combination of docetaxel, cisplatin, and 5-fluorouracil is active and feasible for treating squamous cell carcinoma of the head and neck, with dose level I recommended for further testing.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

CTP-543 is generally safe for treating alopecia areata.

3D ultrasound can detect hair follicle changes and disease phases in alopecia areata.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

DHEA treatment helps grow pubic hair and boosts mood in girls with adrenal issues.

Pumpkin seeds may help expel parasites, but findings are retracted.

This study found that applying a 1% sodium N-(dihydrolipoyl)-l-histidinate zinc complex lotion to the scalp did not prevent chemotherapy-induced alopecia in breast cancer patients, but it may aid recovery.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.